Author:
Ruiz-Boy Sonia,Rodriguez-Reyes Montserrat,Sotoca-Momblona Jose Miguel
Reference5 articles.
1. Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C;Childs-Kean;Infect Drug Resist.,2019
2. Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico de sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) en hepatitis C. Madrid: AEMPS; 2018 [consultado 26 Abr 2020]. Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-sofosbuvir-velpatasvir-voxilaprevir-Vosevi-hepatitisC.pdf?x17133
3. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure;Depasgeri;J Hepatol.,2019
4. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: A large-scale systematic review;Fathi;BMC Infect Dis.,2017